The estimated Net Worth of James Arthur Bristol is at least $303 Tysiąc dollars as of 19 April 2021. James Bristol owns over 7,000 units of Deciphera Pharmaceuticals Inc stock worth over $43,503 and over the last 7 years he sold DCPH stock worth over $0. In addition, he makes $259,448 as Independent Chairman of the Board at Deciphera Pharmaceuticals Inc.
Sign up
James Bristol DCPH stock SEC Form 4 insiders trading
James has made over 12 trades of the Deciphera Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 7,000 units of DCPH stock worth $27,650 on 19 April 2021.
The largest trade he's ever made was exercising 25,000 units of Deciphera Pharmaceuticals Inc stock on 1 November 2019 worth over $47,250. On average, James trades about 9,422 units every 38 days since 2017. As of 19 April 2021 he still owns at least 1,700 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of James Bristol stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Bristol biography
Dr. James Arthur Bristol Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Bristol has served as a member of our Board of Directors since August 2007, as Chairperson since February 2015 and as co-Chairperson from September 2007 to February 2015. Dr. Bristol has also served as Chairperson of the Compensation Committee since September 2017. Dr. Bristol worked for 32 years in drug discovery, research and preclinical development at Schering-Plough Corporation, Parke-Davis, and Pfizer Inc., serving in various senior research and development roles. From 2003 until his retirement in 2007, Dr. Bristol served as Senior Vice President of Worldwide Drug Discovery Research at Pfizer Global Research & Development, where he oversaw 3,000 scientists at seven Pfizer sites as they produced an industry leading number of drug development candidates in 11 therapeutic areas. In 2009, Dr. Bristol joined Frazier Healthcare Ventures as a Senior Advisor. He has served as director of Ignyta, Inc. from 2014 to 2018, Erasca, Inc. since 2018, and Cadent Therapeutics, Inc. since 2011. Dr. Bristol is the author of over 100 publications, abstracts and patents, and he conducted postdoctoral research at the University of Michigan (NIH Postdoctoral Fellow) and at The Squibb Institute for Medical Research. Dr. Bristol holds a Ph.D. in organic chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College.
What is the salary of James Bristol?
As the Independent Chairman of the Board of Deciphera Pharmaceuticals Inc, the total compensation of James Bristol at Deciphera Pharmaceuticals Inc is $259,448. There are 15 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.
How old is James Bristol?
James Bristol is 73, he's been the Independent Chairman of the Board of Deciphera Pharmaceuticals Inc since 2015. There are no older and 19 younger executives at Deciphera Pharmaceuticals Inc.
What's James Bristol's mailing address?
James's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Insiders trading at Deciphera Pharmaceuticals Inc
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar oraz Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
What does Deciphera Pharmaceuticals Inc do?
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
What does Deciphera Pharmaceuticals Inc's logo look like?
Complete history of James Bristol stock trades at Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals Inc executives and stock owners
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Steven Hoerter,
President, Chief Executive Officer, Director -
Michael Taylor,
Director -
Matthew Sherman,
Executive Vice President, Chief Medical Officer -
Thomas Kelly,
Chief Financial Officer, Executive Vice President, Treasurer -
Steven L. Hoerter,
Pres, CEO & Director -
Daniel Flynn,
Founder, Executive Vice President, Chief Scientific Officer -
Dr. Matthew L. Sherman,
Exec. VP & Chief Medical Officer -
Ron Squarer,
Independent Director -
Frank Friedman,
Independent Director -
Thomas Patrick Kelly J.D.,
Exec. VP, CFO & Treasurer -
Dr. Matthew L. Sherman M.D.,
Exec. VP & Chief Medical Officer -
Dr. Daniel L. Flynn,
Exec. VP, Chief Scientific Officer & Founder -
Daniel C. Martin,
Sr. VP & Chief Commercial Officer -
Dr. Stephen B. Ruddy Ph.D.,
Sr. VP & Chief Technical Officer -
Susan Kelley,
Independent Director -
James Bristol,
Independent Chairman of the Board -
Edward Benz,
Independent Director -
Patricia Allen,
Independent Director -
Dennis Walsh,
Independent Director -
John Martin,
Independent Director -
Melissa Forst,
IR Contact Officer -
Lisa Amaya Price,
Sr. VP & Chief HR Officer -
Jennifer Larson,
Sr. VP of Fin. & Investor Relations -
Margarida Duarte,
Sr. VP & Head of International -
Jama Pitman,
Sr. VP of Regulatory, Quality & Portfolio Management -
Jeffrey M. Held J.D.,
Sr. VP & Gen. Counsel -
Jennifer Robinson,
VP of Investor Relations -
Dashyant Dhanak,
EVP & Chief Scientific Officer -
Leaf Venture Management Iii...,
-
Liam Ratcliffe,
Director -
Associates Llc Brightstar,
10% owner -
Christopher John Morl,
Chief Business Officer -
Michael Jay Ross,
Director -
Oliver Rosen,
Chief Medical Officer -
Stephen B. Ruddy,
Chief Technical Officer -
Daniel C. Martin,
Chief Commercial Officer -
Jama Pitman,
SVP, Chief Development Officer